Browsing by Author "Elemento, Olivier"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    An atlas of substrate specificities for the human serine/threonine kinome
    (Springer Nature, 2023) Johnson, Jared L.; Yaron, Tomer M.; Huntsman, Emily M.; Kerelsky, Alexander; Song, Junho; Regev, Amit; Lin, Ting-Yu; Liberatore, Katarina; Cizin, Daniel M.; Cohen, Benjamin M.; Vasan, Neil; Ma, Yilun; Krismer, Konstantin; Torres Robles, Jaylissa; van de Kooij, Bert; van Vlimmeren, Anne E.; Andrée-Busch, Nicole; Käufer, Norbert F.; Dorovkov, Maxim V.; Ryazanov, Alexey G.; Takagi, Yuichiro; Kastenhuber, Edward R.; Goncalves, Marcus D.; Hopkins, Benjamin D.; Elemento, Olivier; Taatjes, Dylan J.; Maucuer, Alexandre; Yamashita, Akio; Degterev, Alexei; Uduman, Mohamed; Lu, Jingyi; Landry, Sean D.; Zhang, Bin; Cossentino, Ian; Linding, Rune; Blenis, John; Hornbeck, Peter V.; Turk, Benjamin E.; Yaffe, Michael B.; Cantley, Lewis C.; Biochemistry and Molecular Biology, School of Medicine
    Protein phosphorylation is one of the most widespread post-translational modifications in biology (1,2). With advances in mass-spectrometry-based phosphoproteomics, 90,000 sites of serine and threonine phosphorylation have so far been identified, and several thousand have been associated with human diseases and biological processes (3,4). For the vast majority of phosphorylation events, it is not yet known which of the more than 300 protein serine/threonine (Ser/Thr) kinases encoded in the human genome are responsible (3). Here we used synthetic peptide libraries to profile the substrate sequence specificity of 303 Ser/Thr kinases, comprising more than 84% of those predicted to be active in humans. Viewed in its entirety, the substrate specificity of the kinome was substantially more diverse than expected and was driven extensively by negative selectivity. We used our kinome-wide dataset to computationally annotate and identify the kinases capable of phosphorylating every reported phosphorylation site in the human Ser/Thr phosphoproteome. For the small minority of phosphosites for which the putative protein kinases involved have been previously reported, our predictions were in excellent agreement. When this approach was applied to examine the signalling response of tissues and cell lines to hormones, growth factors, targeted inhibitors and environmental or genetic perturbations, it revealed unexpected insights into pathway complexity and compensation. Overall, these studies reveal the intrinsic substrate specificity of the human Ser/Thr kinome, illuminate cellular signalling responses and provide a resource to link phosphorylation events to biological pathways.
  • Thumbnail Image
    Item
    Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells
    (Nature Publishing Group, 2014-11) Prasain, Nutan; Lee, Man Ryul; Vemula, Sasidhar; Meador, Jonathan Luke; Yoshimoto, Momoko; Ferkowicz, Michael J.; Fett, Alexa; Gupta, Manav; Rapp, Brian M.; Saadatzadeh, Mohammad Reza; Ginsberg, Michael; Elemento, Olivier; Lee, Younghee; Voytik-Harbin, Sherry L.; Chung, Hyung Min; Hong, Ki Sung; Reid, Emma; O'Neill, Christina L.; Medina, Reinhold J.; Stitt, Alan W.; Murphy, Michael P.; Rafii, Shahin; Broxmeyer, Hal E.; Yoder, Mervin C.; Department of Pediatrics, IU School of Medicine
    The ability to differentiate human pluripotent stem cells into endothelial cells with properties of cord-blood endothelial colony-forming cells (CB-ECFCs) may enable the derivation of clinically relevant numbers of highly proliferative blood vessel-forming cells to restore endothelial function in patients with vascular disease. We describe a protocol to convert human induced pluripotent stem cells (hiPSCs) or embryonic stem cells (hESCs) into cells similar to CB-ECFCs at an efficiency of >10(8) ECFCs produced from each starting pluripotent stem cell. The CB-ECFC-like cells display a stable endothelial phenotype with high clonal proliferative potential and the capacity to form human vessels in mice and to repair the ischemic mouse retina and limb, and they lack teratoma formation potential. We identify Neuropilin-1 (NRP-1)-mediated activation of KDR signaling through VEGF165 as a critical mechanism for the emergence and maintenance of CB-ECFC-like cells.
  • Thumbnail Image
    Item
    Role of RPL39 in Metaplastic Breast Cancer
    (Oxford, 2017) Dave, Bhuvanesh; Gonzalez, Daniel D.; Liu, Zhi-Bin; Li, Xiaoxian; Wong, Helen; Granados, Sergio; Ezzedine, Nadeer E.; Sieglaff, Douglas H.; Ensor, Joe E.; Miller, Kathy D.; Radovich, Milan; Eterovic, Agda Karina; Gross, Steven S.; Elemento, Olivier; Mills, Gordon B.; Gilcrease, Michael Z.; Chang, Jenny C.; Medicine, School of Medicine
    Background: Metaplastic breast cancer is one of the most therapeutically challenging forms of breast cancer because of its highly heterogeneous and chemoresistant nature. We have previously demonstrated that ribosomal protein L39 (RPL39) and its gain-of-function mutation A14V have oncogenic activity in triple-negative breast cancer and this activity may be mediated through inducible nitric oxide synthase (iNOS). The function of RPL39 and A14V in other breast cancer subtypes is currently unknown. The objective of this study was to determine the role and mechanism of action of RPL39 in metaplastic breast cancer. Methods: Both competitive allele-specific and droplet digital polymerase chain reaction were used to determine the RPL39 A14V mutation rate in metaplastic breast cancer patient samples. The impact of RPL39 and iNOS expression on patient overall survival was estimated using the Kaplan-Meier method. Co-immunoprecipitation and immunoblot analyses were used for mechanistic evaluation of RPL39. Results: The RPL39 A14V mutation rate was 97.5% (39/40 tumor samples). High RPL39 (hazard ratio = 0.71, 95% confidence interval = 0.55 to 0.91, P = .006) and iNOS expression (P = .003) were associated with reduced patient overall survival. iNOS inhibition with the pan-NOS inhibitor NG-methyl-L-arginine acetate decreased in vitro proliferation and migration, in vivo tumor growth in both BCM-4664 and BCM-3807 patient-derived xenograft models (P = .04 and P = .02, respectively), and in vitro and in vivo chemoresistance. Mechanistically, RPL39 mediated its cancer-promoting actions through iNOS signaling, which was driven by the RNA editing enzyme adenosine deaminase acting on RNA 1. Conclusion: NOS inhibitors and RNA editing modulators may offer novel treatment options for metaplastic breast cancer.